ArticlePDF Available

Association between Serum Levels of Visfatin and Binge Eating Disorders in Overweight Women

Authors:

Abstract

Introduction: Finding novel molecular-based strategies for effective diagnosis and treatment of diseases is one of the main goal of researchers in the clinical field. Obesity and related obesity and related health problems such as overeating are common problems which have drawn particular attention in the recent years attention in recent years. The aim of this study was to investigate the relationship between serum Visfatin levels and binge eating disorder in overweight women. Materials and Methods: In this study, 70 non-diabetic student women were selected from Shahid Beheshti University with voluntary participation. Sampling was performed under aseptic laboratory conditions and the Gormally overeating questionnaire was completed by each participants. The research hypothesis was that, according to the Gormally questionnaire, there is a significant correlation between serum Visfatin levels and binge eating disorders in overweight women. The statistical analysis was performed using SPSS version 19 software. Results: According to the parametric regression test and coefficient Pearson correlation, it was concluded that there was a significant positive correlation between serum visfatin levels and the scores obtained from the Gormally questionnaire (P = 0.0001, r = 0.99). Conclusion: The findings of this study indicate that the Gormally questionnaire can be used as an appropriate predictor for Visfatin hormone, and vice versa.
A preview of the PDF is not available
Article
Full-text available
Objective: Attention-deficit hyperactivity disorder (ADHD) has a complex etiology and genetic, environmental and biological factors are considered to play a role in the etiology of ADHD by mutually interacting. Recent studies have emphasized that inflammation may be present in the etiology of ADHD. This study aims to investigate the possible role of visfatin, IL-6, IL-1b and TNF-α molecules in the etiology of ADHD. Methods: The study included 60 patients and 20 healthy controls between the ages of 6-18. Serum visfatin, IL-6, IL-1b and TNF-α levels were evaluated with enzyme-linked immunosorbent assay (ELISA) kits at a biochemistry laboratory. Results: The study showed no statistically significant difference between children with ADHD and healthy controls in terms of visfatin, IL-6, IL-1b and TNF-α levels. When ADHD subgroups (combined and predominantly inattentive types) and the control group were compared in terms of visfatin, IL-6, IL-1b and TNF-α levels, no statistically significant difference was recorded. Conclusion: Data on the relationship between ADHD and IL-6, IL-1b and TNF-α in this study are in compliance with the literature. However, no study was found on visfatin in ADHD. This study is the first one evaluating the ADHD-Visfatin relationship.
Article
Full-text available
Adiponectin, apelin, leptin, resistin, and visfatin, as the main circulating peptides secreted by adipose tissue, are potential contributors to bone metabolism. However, their association with bone mineral density (BMD) is unclear. The present study investigated whether these serum adipocytokines levels are associated with BMD and bone turnover markers. Serum adiponectin, apelin, leptin, resistin, visfatin levels, bone turnover biochemical markers, and BMD were determined in 336 post-menopausal Chinese women (41-81 yr old). Adiponectin was negatively correlated with fat mass, while leptin had a positive correlation. In the multiple linear stepwise regression analysis, years since menopause, lean mass, estradiol, and adiponectin, but not fat mass, apelin, leptin, resistin, and visfatin, were independent predictors of BMD. The significant positive correlations between adiponectin and bone-specific alkaline phosphatase, bone crosslinked N-telopeptides of type I collagen were found. Adiponectin was an independent predictor of BMD in post-menopausal Chinese women, and positively correlated with bone turnover biochemical markers. It suggested that adiponectin may exert a negative effect on bone mass by promoting excessive bone resorption associated with bone loss in post-menopausal women.
Article
Full-text available
The IL (interleukin)-6-type cytokines IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an important family of mediators involved in the regulation of the acute-phase response to injury and infection. Besides their functions in inflammation and the immune response, these cytokines play also a crucial role in haematopoiesis, liver and neuronal regeneration, embryonal development and fertility. Dysregulation of IL-6-type cytokine signalling contributes to the onset and maintenance of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, osteoporosis, multiple sclerosis and various types of cancer (e.g. multiple myeloma and prostate cancer). IL-6-type cytokines exert their action via the signal transducers gp (glycoprotein) 130, LIF receptor and OSM receptor leading to the activation of the JAK/STAT (Janus kinase/signal transducer and activator of transcription) and MAPK (mitogen-activated protein kinase) cascades. This review focuses on recent progress in the understanding of the molecular mechanisms of IL-6-type cytokine signal transduction. Emphasis is put on the termination and modulation of the JAK/STAT signalling pathway mediated by tyrosine phosphatases, the SOCS (suppressor of cytokine signalling) feedback inhibitors and PIAS (protein inhibitor of activated STAT) proteins. Also the cross-talk between the JAK/STAT pathway with other signalling cascades is discussed.
Article
Recent studies of obesity show that fat tissue fulfills an endocrine function by producing a variety of secreted proteins, called adipocytokines, that may play key metabolic roles. The present investigators have isolated a newly identified adipocytokine, visfatin, from visceral fat of both mice and humans. Expression of visfatin in the plasma increases as obesity develops. This substance corresponds to a protein identified as preB cell colony-enhancing factor (PBEF), a cytokine expressed in lymphocytes. In a study of 101 human males and females, plasma levels of PBEF correlated closely with the amount of visceral fat as estimated by computed tomography. Correlation with the amount of subcutaneous fat was weak. Significant elevations of PBEF mRNA were also found in KKAy mice, which serve as a model for obesity-related type 2 diabetes. These mice become obese at age 6 to 12 weeks and, at the same time, plasma PBEF levels increase significantly, as do levels of PBEF mRNA in visceral fat. Levels in subcutaneous fat change very little. Mice fed a high-fat diet had higher plasma PBEF concentrations than those fed normal chow. When recombinant visfatin was administered intravenously to c57BL/6J mice, plasma glucose decreased within 30 minutes in a dose-dependent manner. The same effect was noted in insulin-resistant obese KKAy mice, mimicking the effect of insulin injection. Visfatin also had insulin-like effects on cultured cells. In both strains of mice, chronic exposure to visfatin, using adenovirus, significantly lowered plasma levels of both glucose and insulin. Visfatin was found to bind to—and activate—the insulin receptor but in a way different from insulin. These studies indicate that visfatin shares properties of insulin both in vitro and in vivo. In addition to helping to understand glucose and lipid homeostasis and adipocyte proliferation, visfatin may prove to be a useful target when developing drug treatments for diabetes.
Article
Scientific advances in genetics have increased understanding of numerous disorders including many that involve speech, hearing and language. Geneticists utilize recently acquired knowledge in counseling persons who are concerned about the familial transmission of disorders. The article discusses single gene defects and their inheritance, the nature and etiology of chromosomal aberrations, multifactorial traits such as cleft palate, and genetic counseling.
Article
Binge eating disorder (BED) was included in the DSM IV as a proposed diagnostic category for further study and as an example for an eating disorder not otherwise specified (EDNOS). BED is characterized by recurrent episodes of binge eating in the absence of regular compensatory behavior such as vomiting or laxative abuse. Related features include eating until uncomfortably full, eating when not physically hungry, eating alone and feelings of depression or guilt. BED is associated with increased psychopathology including depression and personality disorders. Although BED is not limited to obese individuals, it is most common in this group and those who seek help do so for treatment of overweight rather than for binge eating. In community samples, the prevalence of BED has been found to be 2-5%, in individuals who seek weight control treatment the prevalence is 30%. BED is more equal in gender ratio than bulimia nervosa. Eating disorder treatments such as cognitive behavior therapy (CBT) or interpersonal psychotherapy (IPT) improve binge eating with abstinence rates of about 50%. Antidepressants are also effective in reducing binge eating, though less so than psychotherapy. Standard weight loss treatments including bariatric surgery do not seem to exacerbate binge eating problems. Thus, both eating disorder and obesity treatments seem to be beneficial in BED. However, it is recommended today that treatment should first be directed at the disordered eating and associated psychopathology.
Article
The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) highlights the importance of treating patients with the metabolic syndrome to prevent cardiovascular disease. Limited information is available about the prevalence of the metabolic syndrome in the United States, however. To estimate the prevalence of the metabolic syndrome in the United States as defined by the ATP III report. Analysis of data on 8814 men and women aged 20 years or older from the Third National Health and Nutrition Examination Survey (1988-1994), a cross-sectional health survey of a nationally representative sample of the noninstitutionalized civilian US population. Prevalence of the metabolic syndrome as defined by ATP III (>/=3 of the following abnormalities): waist circumference greater than 102 cm in men and 88 cm in women; serum triglycerides level of at least 150 mg/dL (1.69 mmol/L); high-density lipoprotein cholesterol level of less than 40 mg/dL (1.04 mmol/L) in men and 50 mg/dL (1.29 mmol/L) in women; blood pressure of at least 130/85 mm Hg; or serum glucose level of at least 110 mg/dL (6.1 mmol/L). The unadjusted and age-adjusted prevalences of the metabolic syndrome were 21.8% and 23.7%, respectively. The prevalence increased from 6.7% among participants aged 20 through 29 years to 43.5% and 42.0% for participants aged 60 through 69 years and aged at least 70 years, respectively. Mexican Americans had the highest age-adjusted prevalence of the metabolic syndrome (31.9%). The age-adjusted prevalence was similar for men (24.0%) and women (23.4%). However, among African Americans, women had about a 57% higher prevalence than men did and among Mexican Americans, women had about a 26% higher prevalence than men did. Using 2000 census data, about 47 million US residents have the metabolic syndrome. These results from a representative sample of US adults show that the metabolic syndrome is highly prevalent. The large numbers of US residents with the metabolic syndrome may have important implications for the health care sector.
Article
Obesity is a complex disease that involves interactions between environmental and genetic factors. Obesity results from an imbalance between food intake and energy expenditure over several years. The genetic approach both in animal models and in humans has allowed immense progress in the understanding of body weight regulation. Monogenic forms of obesity in humans have been characterized and result from mutations in genes involved in the central pathways of food intake regulation. However, these cases are extremely rare and generally obesity must be considered as a complex polygenic disease involving interactions between multiple genes and the environment. Numerous studies, including studies in children, have tried to identify "susceptibility" genes. At present, the results are not conclusive inasmuch as they are highly variable between studies and because the relative risk associating a specific gene allele and obesity remains low. Thus, it seems highly premature to genotype obese patients on a large scale for predictive testing. When specific pharmacological treatments based on recent discoveries become available, however, genetic testing could help discriminate between the subtypes of obesity that may respond differentially to treatment.
Article
In this study, we investigated whether the variant of the beta3-adrenoceptor gene is associated with accumulation of body fat in Japanese junior high school students. A total of 87 junior high school students, 50 boys and 37 girls, participated in this survey. The beta3-adrenoceptor gene variant was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Accumulation of body fat was assessed by skinfold thickness at the triceps and subscapular with a skinfold caliper. There was no difference between boys and girls in the frequency of the beta3-adrenoceptor gene allele. There were no significant differences in body mass index and percent body fat between the Arg carriers (Trp/Arg or Arg/Arg) and the Arg noncarriers (Trp/Trp) for either sex. The Trp64Arg variant of the beta3-adrenoceptor gene does not seem to have a strong effect on the accumulation of body fat in this group of Japanese junior high school students.
Article
Fat tissue produces a variety of secreted proteins (adipocytokines) with important roles in metabolism. We isolated a newly identified adipocytokine, visfatin, that is highly enriched in the visceral fat of both humans and mice and whose expression level in plasma increases during the development of obesity. Visfatin corresponds to a protein identified previously as pre-B cell colony-enhancing factor (PBEF), a 52-kilodalton cytokine expressed in lymphocytes. Visfatin exerted insulin-mimetic effects in cultured cells and lowered plasma glucose levels in mice. Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild-type littermates. Surprisingly, visfatin binds to and activates the insulin receptor. Further study of visfatin's physiological role may lead to new insights into glucose homeostasis and/or new therapies for metabolic disorders such as diabetes.
Article
Nicotinamide phosphoribosyltransferase (Nampt) synthesizes nicotinamide mononucleotide (NMN) from nicotinamide in a mammalian NAD+ biosynthetic pathway and is required for SirT1 activity in vivo. Nampt has also been presumed to be a cytokine (PBEF) or a hormone (visfatin). The crystal structure of Nampt in the presence and absence of NMN shows that Nampt is a dimeric type II phosphoribosyltransferase and provides insights into the enzymatic mechanism.